Maxivision Super Specialty Eye Hospitals, chaired by G.S.K. Velu, is planning a significant expansion in western India ahead of its public listing scheduled for next year, according to livemint.com. The company aims to strengthen its presence in this region as part of its growth strategy before the initial public offering (IPO).
The expansion follows a sequence of listings involving companies chaired by Velu. Neuberg Diagnostics, where Velu also serves as chairman, is expected to be the first to go public, followed by Maxivision Eye Hospitals and then Trivitron Healthcare, a medtech firm also led by Velu. This phased approach indicates a coordinated effort to capitalize on market opportunities across healthcare segments.
This move is significant in the context of India's growing healthcare sector, where diagnostic and specialty hospital chains are increasingly attracting investor interest. Maxivision’s planned IPO aligns with broader trends of healthcare companies seeking public capital to fund expansion, improve infrastructure, and enhance service delivery. The involvement of multiple firms under Velu’s leadership highlights a strategic positioning within the healthcare market.
Maxivision’s targeted west India expansion and its IPO next year mark key milestones in its growth trajectory. Neuberg Diagnostics’ listing is anticipated to precede Maxivision’s, setting a precedent for the group’s public market entries, as reported by livemint.com.